Note 8 - Subsequent Events	12 Months Ended
Dec. 31, 2020
Notes to Financial Statements
Subsequent Events [Text Block]	Note 8: Subsequent Events Management continues to actively monitor the COVID-19 pandemic and its development, and the possible effects on the Company’s financial condition, liquidity, operations, vendors, industry, and workforce. For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through March 30, 2021, the date the consolidated financial statements were available to be issued. Except as discussed below, management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements. *Stock Option Grant* On January 4, 2021, the Company granted to executives and key personnel an aggregate of 417,500 stock options with an exercise price of $5.16. The options will vest in one year from the date of grant or annually in equal installments over four years. On January 4, 2021, the Company granted to members of the Board an aggregate of 227,500 stock options with an exercise price of $5.16. The options will vest in one year from the date of grant. On January 4, 2021, the Company granted to non-executive employees an aggregate of 23,325 stock options with an exercise price of $5.16. The options will vest in one year from the date of grant. On January 4, 2021, the Company granted 5,000 stock options to a consultant with an exercise price of $5.16. The options will vest in one year from the date of grant. On January 21, 2021, the Company granted 7,500 stock options to a consultant with an exercise price of $5.65. The options will vest in one year from the date of grant. On March 22, 2021, the Company granted 30,000 stock options to a consultant with an exercise price of $6.87. The options will vest in one year from the date of grant. *Appointment of New Director* On January 8, 2021, Patrick Lucy was appointed to the Board. Mr. Lucy serves as a member of the Board’s Science and Technology Committee. As a non-employee director of the Company, Mr. Lucy receives annual cash compensation of $60,000 and a new director grant of 35,000 options at an exercise price of $5.50. The options will vest in one year from the date of grant.

Note 8 - Subsequent Events

12 Months Ended

Dec. 31, 2020

Note 8: Subsequent Events

Management continues to actively monitor the COVID-19 pandemic and its development, and the possible effects on the Company’s financial condition, liquidity, operations, vendors, industry, and workforce.

For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through March 30, 2021, the date the consolidated financial statements were available to be issued. Except as discussed below, management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.

Stock Option Grant

On January 4, 2021, the Company granted to executives and key personnel an aggregate of 417,500 stock options with an exercise price of $5.16. The options will vest in one year from the date of grant or annually in equal installments over four years.

On January 4, 2021, the Company granted to members of the Board an aggregate of 227,500 stock options with an exercise price of $5.16. The options will vest in one year from the date of grant.

On January 4, 2021, the Company granted to non-executive employees an aggregate of 23,325 stock options with an exercise price of $5.16. The options will vest in one year from the date of grant.

On January 4, 2021, the Company granted 5,000 stock options to a consultant with an exercise price of $5.16. The options will vest in one year from the date of grant.

On January 21, 2021, the Company granted 7,500 stock options to a consultant with an exercise price of $5.65. The options will vest in one year from the date of grant.

On March 22, 2021, the Company granted 30,000 stock options to a consultant with an exercise price of $6.87. The options will vest in one year from the date of grant.

Appointment of New Director

On January 8, 2021, Patrick Lucy was appointed to the Board. Mr. Lucy serves as a member of the Board’s Science and Technology Committee. As a non-employee director of the Company, Mr. Lucy receives annual cash compensation of $60,000 and a new director grant of 35,000 options at an exercise price of $5.50. The options will vest in one year from the date of grant.